NASDAQ:GTHX G1 Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding G1 Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $15.23 -0.41 (-2.62 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$14.96Now: $15.23▼$15.8750-Day Range$14.67MA: $15.58▼$16.7152-Week Range$8.80Now: $15.23▼$36.35Volume2.06 million shsAverage Volume480,406 shsMarket Capitalization$578.97 millionP/E RatioN/ADividend YieldN/ABeta1.97 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.Read More Beat the Market (BTM) Rank™ 4.5 Analyst's Opinion Consensus RatingG1 Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $59.29, G1 Therapeutics has a forecasted upside of 289.3% from its current price of $15.23.Amount of Analyst CoverageG1 Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.4 Community Rank Outperform VotesG1 Therapeutics has received 266 “outperform” votes. (Add your “outperform” vote.)Underperform VotesG1 Therapeutics has received 284 “underperform” votes. (Add your “underperform” vote.)Community SentimentG1 Therapeutics has received 51.64% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about G1 Therapeutics and other stocks. Vote “Outperform” if you believe GTHX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GTHX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldG1 Therapeutics does not currently pay a dividend.Dividend GrowthG1 Therapeutics does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, G1 Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $14,950.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 15.92% of the stock of G1 Therapeutics is held by insiders.Percentage Held by Institutions75.79% of the stock of G1 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for G1 Therapeutics are expected to decrease in the coming year, from ($2.83) to ($3.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of G1 Therapeutics is -4.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of G1 Therapeutics is -4.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioG1 Therapeutics has a P/B Ratio of 2.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.18 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GTHX Previous Symbol CUSIPN/A CIK1560241 Webwww.g1therapeutics.com Phone919-213-9835Debt Debt-to-Equity Ratio0.14 Current Ratio10.95 Quick Ratio10.95Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.80 per share Price / Book2.24Profitability EPS (Most Recent Fiscal Year)($3.27) Net Income$-122,450,000.00 Net MarginsN/A Return on Equity-53.35% Return on Assets-46.77%Miscellaneous Employees84 Outstanding Shares38,015,000Market Cap$578.97 million Next Earnings Date11/3/2020 (Estimated) OptionableOptionable $15.23 -0.41 (-2.62 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive GTHX News and Ratings via Email Sign-up to receive the latest news and ratings for GTHX and its competitors with MarketBeat's FREE daily newsletter. G1 Therapeutics (NASDAQ:GTHX) Frequently Asked Questions How has G1 Therapeutics' stock price been impacted by COVID-19 (Coronavirus)? G1 Therapeutics' stock was trading at $14.49 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, GTHX shares have increased by 5.1% and is now trading at $15.23. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of G1 Therapeutics? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for G1 Therapeutics. When is G1 Therapeutics' next earnings date? G1 Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for G1 Therapeutics. How were G1 Therapeutics' earnings last quarter? G1 Therapeutics Inc (NASDAQ:GTHX) issued its earnings results on Wednesday, August, 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.83). The company had revenue of $2.14 million for the quarter, compared to the consensus estimate of $6 million. View G1 Therapeutics' earnings history. What price target have analysts set for GTHX? 8 equities research analysts have issued 12 month price objectives for G1 Therapeutics' shares. Their forecasts range from $23.00 to $82.00. On average, they anticipate G1 Therapeutics' stock price to reach $59.29 in the next year. This suggests a possible upside of 289.3% from the stock's current price. View analysts' price targets for G1 Therapeutics. Are investors shorting G1 Therapeutics? G1 Therapeutics saw a increase in short interest in the month of August. As of August 14th, there was short interest totaling 4,300,000 shares, an increase of 19.8% from the July 30th total of 3,590,000 shares. Based on an average trading volume of 603,700 shares, the days-to-cover ratio is currently 7.1 days. Currently, 15.5% of the shares of the company are short sold. View G1 Therapeutics' Short Interest. Who are some of G1 Therapeutics' key competitors? Some companies that are related to G1 Therapeutics include Karuna Therapeutics (KRTX), Aimmune Therapeutics (AIMT), Taro Pharmaceutical Industries (TARO), Opko Health (OPK), Intra-Cellular Therapies (ITCI), Revance Therapeutics (RVNC), I-Mab (IMAB), Corcept Therapeutics (CORT), Zymeworks (ZYME), Humanigen (HGEN), Eidos Therapeutics (EIDX), CytoDyn (CYDY), Myovant Sciences (MYOV), Aurinia Pharmaceuticals (AUPH) and Seres Therapeutics (MCRB). View all competitors. What other stocks do shareholders of G1 Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Johnson & Johnson (JNJ), Rite Aid (RAD), Gilead Sciences (GILD), Kadmon (KDMN), Novavax (NVAX) and Viking Therapeutics (VKTX). Who are G1 Therapeutics' key executives? G1 Therapeutics' management team includes the following people: Dr. Mark A. Velleca, CEO, Pres & Director (Age 55)Mr. James Stillman Hanson, Gen. Counsel (Age 47)Mr. Terry L. Murdock, Sr. VP of Devel. Operations (Age 59)Mr. John Demaree, Chief Commercial Officer (Age 52)Ms. Jennifer K. Moses, Chief Financial Officer (Age 44) When did G1 Therapeutics IPO? (GTHX) raised $101 million in an initial public offering on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers. What is G1 Therapeutics' stock symbol? G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX." Who are G1 Therapeutics' major shareholders? G1 Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (14.89%), FMR LLC (14.89%), Vanguard Group Inc. (5.41%), Candriam Luxembourg S.C.A. (2.31%), Bank of America Corp DE (0.70%) and Goldman Sachs Group Inc. (0.66%). Company insiders that own G1 Therapeutics stock include Barclay A Phillips, Cynthia Schwalm, James S Hanson, Jennifer K Moses, John Demaree, Mark A Velleca, Rajesh Malik, Seth Rudnick and Terry L Murdock. View institutional ownership trends for G1 Therapeutics. Which major investors are selling G1 Therapeutics stock? GTHX stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Alps Advisors Inc., UBS Group AG, California Public Employees Retirement System, and SG Americas Securities LLC. View insider buying and selling activity for G1 Therapeutics. Which major investors are buying G1 Therapeutics stock? GTHX stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Raymond James & Associates, Federated Hermes Inc., Point72 Asset Management L.P., Goldman Sachs Group Inc., CHI Advisors LLC, PDT Partners LLC, and Raymond James Financial Services Advisors Inc.. Company insiders that have bought G1 Therapeutics stock in the last two years include Cynthia Schwalm, James S Hanson, and John Demaree. View insider buying and selling activity for G1 Therapeutics. How do I buy shares of G1 Therapeutics? Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is G1 Therapeutics' stock price today? One share of GTHX stock can currently be purchased for approximately $15.23. How big of a company is G1 Therapeutics? G1 Therapeutics has a market capitalization of $578.97 million. The company earns $-122,450,000.00 in net income (profit) each year or ($3.27) on an earnings per share basis. G1 Therapeutics employs 84 workers across the globe. What is G1 Therapeutics' official website? The official website for G1 Therapeutics is www.g1therapeutics.com. How can I contact G1 Therapeutics? G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The company can be reached via phone at 919-213-9835 or via email at [email protected] This page was last updated on 9/20/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
